Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1


About this study

This study is being done to better understand the relationship between inflammation in your AT, abnormal deposition of fat around your liver and how this affects its appearance and function and ultimately insulin resistance.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Undergoing RYGBS or Sleeve Gastrectomy surgery.
  • Confirmed AUROC F = 0 or F > 2 liver fibrosis
  • Age 30-70 years.
  • BMI greater than 35 kg/m^2.
  • Negative pregnancy test (female only).
  • Lab Values: Normal TSH.
  • Type 2 Diabetes.

Exclusuion Criteria:

  • Autoimmune diseases.
  • Hepatitis B or C positive.
  • Heavy alcohol use.
  • Active smoking history.
  • Active cancer history.
  • History of asthma.
  • History of COPD.
  • Taking Plavix or Coumadin.
  • Taking any Glucagon-like Peptide 1 receptor agonist (GLP-1RA).
  • Blood donation within past 2 months.
  • Glucocorticoid therapy.
  • Taking antihistamine on regular basis.

Eligibility last updated 10/17/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Elena Anna De Filippis, M.D., Ph.D.

Open for enrollment

Contact information:

Keegan Stewart M.S.

(480) 301-4164

More information


Publications are currently not available

Mayo Clinic Footer